ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.Celastrol was identified as being a Myb inhibitor that suppressed C/EBPβ activity and represse